Amlodipine New Zealand - English - Medsafe (Medicines Safety Authority)

amlodipine

ipca pharma (nz) pty limited - amlodipine besilate 13.88mg equivalent to 10 mg amlodipine;   - tablet - 10 mg - active: amlodipine besilate 13.88mg equivalent to 10 mg amlodipine   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose sodium starch glycolate - amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor.

Amlodipine New Zealand - English - Medsafe (Medicines Safety Authority)

amlodipine

norton healthcare limited (nz) - amlodipine besilate 13.888mg equivalent to 10 mg amlodipine - tablet - 10 mg - active: amlodipine besilate 13.888mg equivalent to 10 mg amlodipine excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose sodium starch glycolate

I-Amlodipine New Zealand - English - Medsafe (Medicines Safety Authority)

i-amlodipine

ipca pharma (nz) pty limited - amlodipine besilate 13.88mg equivalent to 10 mg amlodipine;   - tablet - 10 mg - active: amlodipine besilate 13.88mg equivalent to 10 mg amlodipine   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose sodium starch glycolate - amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor.

Arrow - Amlo 10 New Zealand - English - Medsafe (Medicines Safety Authority)

arrow - amlo 10

actavis new zealand limited - amlodipine besilate 13.88mg equivalent to 10 mg amlodipine;   - tablet - 10 mg - active: amlodipine besilate 13.88mg equivalent to 10 mg amlodipine   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose sodium starch glycolate - amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor.

Arrow - Amlodipine 10 New Zealand - English - Medsafe (Medicines Safety Authority)

arrow - amlodipine 10

actavis new zealand limited - amlodipine besilate 13.88mg equivalent to amlodipine 10.0 mg - tablet - 10 mg - active: amlodipine besilate 13.88mg equivalent to amlodipine 10.0 mg excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose sodium starch glycolate water

Tenox Tablets 10 mg Singapore - English - HSA (Health Sciences Authority)

tenox tablets 10 mg

singapore pharmaceutical private limited - amlodipine besilate 13.88 mg equivalent to amlodipine - tablet - 10mg - amlodipine besilate 13.88 mg equivalent to amlodipine 10mg

CADIVAST 10/80 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/80 mg tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cadivast 10/80 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/80 mg tablets bottle

alphapharm pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg); atorvastatin calcium trihydrate, quantity: 86.751 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; arginine; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; colloidal anhydrous silica; sodium carbonate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; indigo carmine aluminium lake - amlodipine besilate and atorvastatin calcium trihydrate tablet is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented.,the indications for amlodipine are:,1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are:,1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials, atorvastatin component, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

CADIVAST 10/10 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/10 mg tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cadivast 10/10 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/10 mg tablets bottle

alphapharm pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg); atorvastatin calcium trihydrate, quantity: 10.844 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium carbonate; arginine; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; croscarmellose sodium; hyprolose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; indigo carmine aluminium lake - amlodipine besilate and atorvastatin calcium trihydrate tablet is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented.,the indications for amlodipine are:,1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are:,1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials, atorvastatin component, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

BESIDEP amlodipine besylate 10 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

besidep amlodipine besylate 10 mg tablet blister pack

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

CADIVAST 10/20 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/20 mg tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cadivast 10/20 amlodipine (as besilate) and atorvastatin (as calcium) 10 mg/20 mg tablets bottle

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 21.688 mg (equivalent: atorvastatin, qty 20 mg); amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: arginine; sodium carbonate; croscarmellose sodium; colloidal anhydrous silica; hyprolose; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; indigo carmine aluminium lake - amlodipine besilate and atorvastatin calcium trihydrate tablet is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented.,the indications for amlodipine are:,1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are:,1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials, atorvastatin component, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.